1.17
0.00 (0.00%)
| Previous Close | 1.17 |
| Open | 1.09 |
| Volume | 238,707 |
| Avg. Volume (3M) | 686,335 |
| Market Cap | 58,285,184 |
| Price / Sales | 0.800 |
| Price / Book | 6.45 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2025 - 16 May 2025 |
| Profit Margin | -59.44% |
| Operating Margin (TTM) | -79.73% |
| Diluted EPS (TTM) | -0.960 |
| Quarterly Revenue Growth (YOY) | -9.30% |
| Total Debt/Equity (MRQ) | 1,107.91% |
| Current Ratio (MRQ) | 0.610 |
| Operating Cash Flow (TTM) | -30.49 M |
| Levered Free Cash Flow (TTM) | -15.14 M |
| Return on Assets (TTM) | -17.49% |
| Return on Equity (TTM) | -354.27% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Bullish | Mixed | |
| Stock | Akoya BioSciences, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -3.5 |
| Technical Oscillators | 0.0 |
| Average | -1.57 |
|
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler® (formerly CODEX) and PhenoImager® (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Value |
| % Held by Insiders | 72.58% |
| % Held by Institutions | 69.80% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Peddock Capital Advisors, Llc | 30 Sep 2024 | 234,720 |
| Osterweis Capital Management Inc | 30 Sep 2024 | 126,131 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |